Navigation Links
Mylan Announces Move to NASDAQ Stock Market
Date:12/12/2008

PITTSBURGH, Dec. 12 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that it will move its stock exchange listing to The NASDAQ Stock Market, an exchange of The NASDAQ OMX Group Inc. (Nasdaq: NDAQ), from The New York Stock Exchange (NYSE) effective Dec. 29. The company will be listed on the NASDAQ Global Select Market, and its common stock will continue to trade under the "MYL" ticker symbol.

Mylan's Vice Chairman and CEO Robert J. Coury commented: "Notwithstanding the obvious financial benefits that NASDAQ offers, the decision to switch Mylan's listing was also driven by the fact that for quite some time a greater portion of our total trading volume was already crossing on NASDAQ trading facilities. This decision, we believe, will further enhance Mylan's overall needs and efficiencies."

Mylan's mandatory convertible preferred stock and 1.25% convertible notes also will move to NASDAQ with the ticker symbols "MYLNP" and "MYLNG," respectively.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
2. Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules
3. Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately
4. Mylan Declares Quarterly Preferred Stock Dividend
5. Mylans Matrix First-to-File on Generic Version of Vfend(R) Antifungal
6. Mylan to Retain Dey, L.P., Its Specialty Pharmaceutical Subsidiary
7. Mylan to Offer $400 Million in Cash Convertible Notes
8. Mylan Creates New Womens Health Care Franchise; Signs Agreement with Famy Care to Develop and Supply 22 Oral Contraceptive Products
9. Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008
10. Mylan Declares Quarterly Preferred Stock Dividend
11. Mylan Schedules Financial Results Conference Call and Live Webcast for the Second Quarter Fiscal 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10How to reduce hospital stays and increase patient satisfaction 58689 1How to reduce hospital stays and increase patient satisfaction 58689 2Natural killer cells keep immune system in balance 10226 1Natural killer cells keep immune system in balance 10226 2Ardi displaces Lucy as oldest hominid skeleton 10222 1Ardi displaces Lucy as oldest hominid skeleton 10222 2Ardi displaces Lucy as oldest hominid skeleton 10222 3Ardi displaces Lucy as oldest hominid skeleton 10222 4Ardi displaces Lucy as oldest hominid skeleton 10222 5